Globally, 10 million new cases every year and 4000 people die every day due to Tuberculosis (TB). TB is curable if detected at early stages and treated with correct antibiotics. If not, the TB bacteria develops resistance and becomes a challenge for diagnosis and treatment. Rapid and accurate detection of multi-drug resistant (MDR) strains is urgently needed to effectively treat patients and prevent spreading of drug-resistant TB in the community.
EMPE Diagnostics AB, Sweden has developed mfloDx® technology that can rapidly detect the TB causing bacteria and its drug-resistance profiles in less than 3 hours, directly from patients’ sputum samples. The mfloDx® is a technology platform that is customizable to detect any DNA or RNA transcripts. Presently, we are releasing single-use diagnostic test kits for TB and expand our portfolio to sexually transmitted diseases.
The first product miniMDR-TB is released for research use only during Q2 2020. The second product, which is the first flagship of EMPE Diagnostics is ready to be released for Research use.
Company’s Keywords:
in vitro diagnostics, infectious diseases, tuberculosis, biotechnology, sexually transmitted diseases, lateral flow technology, padlock probe & rolling circle amplification, drug resistance
25
medical devices
Gmail, Google Apps, Apache, Mobile Friendly, Varnish, WordPress.org, Bootstrap Framework, Google Font API
2015
Your request has been submitted successfully.
Own or work here?